Leah Kuntz

Cannabis withdrawal syndrome impacts approximately half of those who use it regularly. How can you help patients cease cannabis use?

Review tapering challenges and strategies for benzodiazepines in this Special Report article.

Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints, according to new study.

Following the vote of the US Food and Drug Administration Psychopharmacologic Drugs Advisory Committee, Lykos has released a statement on MDMA-assisted therapy.

With cannabis legalization increasing in the United States, so too are the issues surrounding cannabis access, usage, and use disorders. State by state, take a peek at some of the issues and updates surrounding cannabis.

Transgender individuals are 4 times as likely as their cisgender peers to have a mental illness. Check out these culturally competent care strategies and tips to provide the best possible care.

The FDA Advisory Committee recommended donanemab, which could lead to its approval later this year.

Andrew Krystal, MD, and Wayne Drevets, MD, share their thoughts on the recent seltorexant data presented at the 2024 ASCP Annual Meeting.

The FDA Psychopharmacologic Drugs Advisory Committee voted against recommending approval for psychedelic MDMA.

The FDA Meeting of the Psychopharmacologic Drugs Advisory Committee evaluating the New Drug Application for MDMA is happening now. How do clinicians feel about this potential treatment for PTSD?

Rakesh Jain, MD, shares more about the recent approval of Austedo XR for the treatment of tardive dyskinesia and Huntington disease chorea control.

Investigators have dosed the first participant in a new study investigating the neurophysiological effects of BPL-003.

A lead educator and clinical consultant in the Lykos Therapeutics MDMA Therapist Education Program discusses MDMA-assisted therapy’s potential.

Some clinicians are skeptical about the potential of MDMA-assisted therapy...

If approved, how will MDMA-assisted therapy impact clinical psychiatry? The CEO of Lykos Therapeutics shares her thoughts.

In advance of the June 4 FDA Advisory Committee Meeting on MDMA-assisted therapy, we sat down with Alejandra Alva, MD, to get his first impressions.

Research on MDD treatments seltorexant and Spravato (esketamine) CIII nasal spray shared at 2024 ASCP Annual Meeting.

The FDA has approved Austedo XR as a once-daily pill treatment option for tardive dyskinesia and Huntington disease chorea control.

Onyda XR is the first and only liquid nonstimulant ADHD medication approved in the US and the only approved nonstimulant ADHD medication with nighttime dosing.

Investigators at McLean Hospital found 61% and 45% of individuals still experiencing binge-eating disorder after 2.5 and 5 years after their initial diagnoses, respectively.

Sam Clark, MD, PhD, the founder and CEO of Terran Biosciences shared all you need to know about the development of their schizophrenia treatment, TerXT.

In honor of Asian American/Pacific Islander Heritage Month, we had a discussion on how best to support AAPI youth and their families.

Check out new data from phase 3 study of Ingrezza for the real-world management of tardive dyskinesia.

A recent study analyzed longitudinal data of patients with schizophrenia or major depressive disorder to rank treatment regimens in terms of weight gain, adverse effects, and response to treatment.

The latest in mood disorder news, all in one place.

Eisai and Biogen announced they have initiated a rolling submission for subcutaneous Leqembi for Alzheimer disease.

H. Steven Moffic, MD, received the Abraham Halpern Humanitarian Award at the 2024 American Psychiatric Association Annual Meeting. Here’s what he spoke about during his acceptance.

TEV-‘749, an investigational once-monthly subcutaneous long-acting injection of the 2nd generation antipsychotic olanzapine, sees positive phase 3 results.

This 2024 APA Annual Meeting poster documented the abuse potential of benzodiazepines and tapering challenges.

This 2024 APA Annual Meeting poster estimated the prevalence of tardive dyskinesia in antipsychotic users in the US, and found rates ranging from 94.1-127.4 per 1000 antipsychotic users.